D005909DisordersC04.557.465.625.600.380.080.335C04.557.470.670.380.080.335C04.557.580.625.600.380.080.3358100.980309GlioblastomaFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation Resourcevivo:orcidIdORCID idPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonMarkusWimmerMarkus A. Wimmer41.87352120000000-87.66713820000000349100Wimmer, Markus0000-0001-6169-3873ProfessorRichardByrneRichard Byrne349198Byrne, RichardProfessorLeiDuanLei Duan349250Duan, LeiAssistant Professor6Assistant Professor4Professortrue1ProfessorProfessor32166308Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MRNeuro-oncologyA Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro Oncol. 2020 10 14; 22(10):1505-1515.Neuro Oncol2020-10-14T00:00:002020A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma.1.770920.01865948research area of0.9382270.076136722subject area for33482415Nunna RS, Khalid SI, Patel S, Sethi A, Behbahani M, Mehta AI, Adogwa O, Byrne RWWorld neurosurgeryOutcomes and Patterns of Care in Elderly Patients with Glioblastoma Multiforme. World Neurosurg. 2021 05; 149:e1026-e1037.World Neurosurg2021-01-20T00:00:002021Outcomes and Patterns of Care in Elderly Patients with Glioblastoma Multiforme.Orthopedic SurgeryAnatomy and Cell BiologyFamily MedicineRush University, Rush Medical CollegeJoshuaJacobsJoshua J. Jacobs41.87352120000000-87.66713820000000349020Jacobs, Joshua0000-0003-3902-7334Professortrue1Assistant ProfessorAssistant Professor34716726Tira A, Buckingham LInternational journal of experimental pathologyEvidence for age-related contributions of DNA damage and epigenetics in brain tumorigenesis. Int J Exp Pathol. 2021 12; 102(6):232-241.Int J Exp Pathol2021-10-30T00:00:002021Evidence for age-related contributions of DNA damage and epigenetics in brain tumorigenesis.34981417Dong Q, Wang D, Li L, Wang J, Li Q, Duan L, Yin H, Wang X, Liu Y, Yuan G, Pan YMolecular neurobiologyBiochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy. Mol Neurobiol. 2022 Feb; 59(2):1262-1272.Mol Neurobiol2022-01-04T00:00:002022Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy.true1Assistant ProfessorAssistant ProfessorNeurological SurgeryKateRowlandKate Rowland349986Rowland, KateAssistant Professortrue1ProfessorProfessortrue1ProfessorProfessor37175636Brandt B, N?meth M, Berta G, Sz?nstein M, Heffer M, Rauch TA, Pap MInternational journal of molecular sciencesA Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines. Int J Mol Sci. 2023 Apr 27; 24(9).Int J Mol Sci2023-04-27T00:00:002023A Promising Way to Overcome Temozolomide Resistance through Inhibition of Protein Neddylation in Glioblastoma Cell Lines.